Pyxis Oncology, Inc.
About Pyxis Oncology, Inc.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $13.9M
- Net income
- -$79.6M
- Total assets
- $91.5M
- Market cap
- $112.8M
- Gross margin
- 82.8%
- Operating margin
- -609.2%
- Net margin
- -574.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $13.9M
- Cost of revenue
- $2.4M
- Gross profit
- $11.5M
- Operating expenses
- $95.9M
- Operating income
- -$84.4M
- Income tax
- $1.4M
- Net income
- -$79.6M
- EPS (basic)
- $-1.28
- EPS (diluted)
- $-1.28
Balance sheet
- Total assets
- $91.5M
- Current assets
- $72.1M
- Total liabilities
- $38.1M
- Current liabilities
- $21.1M
- Shareholders’ equity
- $53.4M
Cash flow
- Operating cash flow
- -$63.5M
- Investing cash flow
- $58.9M
- Financing cash flow
- $594.0K
- Net cash flow
- -$4.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $112.8M
- EPS (diluted)
- $-1.28
- Shares outstanding
- 66.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $79.6M in FY2025.
- Gross margin of 82.8%, net margin -574.5%.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pyxis Oncology, Inc..
Write a review
News about Pyxis Oncology, Inc.
News & sentiment via Polygon.io
